Pay in 4 interest-free payments of $6.90 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Beyond GLP-1, the market encompasses peptide cancer therapies (Oncology Peptide Therapy at 4.1% share, 11.79% CAGR), somatostatin analogues for neuroendocrine tumours, GnRH agonists/antagonists for hormone-sensitive cancers, radioligand therapy, and reproductive medicine peptides each representing strategically important niches with their own competitive dynamics
Order before 4 PM PST for same-business-day shipping
After completion of initial consult, a treatment can usually be scheduled in less than 1 week
For many patients, this involves combination therapy using: PT-141 injections (Bremetide) to activate sexual desire and central arousal PDE5 inhibitors or compounded therapies like Erexafil to boost blood flow and erectile response Hormone replacement therapy is recommended if low testosterone is identified Sublingual medications for rapid-onset enhancement when needed This protocol also considers comorbidities such as high blood pressure, diabetes, or neurological conditions, ensuring that treatment is safe, effective, and aligned with broader health goals
The left side of the figure describes small molecule GLP-1 receptor agonists currently in the process of drug development
